Search

Displaying results 1741 - 1750 of 10000 in total
  1. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". … In its composition it presents some fatty acids such as [DB00132] and [DB13854].

    Mixtures: PRIM E CAPSULE, Evening Primrose Oil With Vitamin EProducts: Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA), Nn EVENING PRIMROSE OIL 500MG (with 10% GLA)
  2. Drug

    Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15705
    ApprovedInvestigationalWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

    Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer Fertigspritze
  3. Drug

    Influenza B virus B/Utah/9/2014 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB11002
    ApprovedWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

    Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016, Medical Provider Single Use EZ Flu Shot 2018-2019
  4. Drug

    Manganese citrate

    go.drugbank.com/drugs/DB14495
    Approved

    Mixtures: Collag-EN
  5. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia. … Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  6. Drug

    Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15706
    ApprovedInvestigationalWithdrawn

    There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

    Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer Fertigspritze
  7. Drug

    Picosulfuric acid

    go.drugbank.com/drugs/DB09268
    ApprovedInvestigational

    The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322] … Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery.

    Mixtures: AGAROL CON SABOR A FRAMBUESA
  8. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017. … [L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682]

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]

  10. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Lusutrombopag binds to the transmembrane domain of TPOR expressed on megakaryocytes, and causes the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells [FDA